{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T21:30:16Z","timestamp":1793568616629,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jaut.2018.09.002","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T02:06:37Z","timestamp":1536631597000},"page":"108-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Efficacy of the anti-IL 17 secukinumab in refractory Beh\u00e7et's syndrome: A preliminary study"],"prefix":"10.1016","volume":"97","author":[{"given":"Gerardo","family":"Di Scala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bettiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela Diana","family":"Cojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6254-3161","authenticated-orcid":false,"given":"Martina","family":"Finocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2018.09.002_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11739-013-1036-5","article-title":"Beh\u00e7et\u2019s syndrome pathophysiology and potential therapeutic targets","volume":"9","author":"Emmi","year":"2014","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.jaut.2018.09.002_bib2","article-title":"Beh\u00e7et syndrome: a contemporary view","author":"Yazici","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2018.09.002_bib3","first-page":"46","article-title":"What affects the quality of life in patients with Behcet's disease?","volume":"39","author":"Melikoglu","year":"2014","journal-title":"Acta Reumatol. Port."},{"key":"10.1016\/j.jaut.2018.09.002_bib4","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.09.002_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for beh\u00e7et\u2019s syndrome - a phase 2, placebo-controlled study","author":"Hatemi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2018.09.002_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/1744666X.2016.1205486","article-title":"Behcet's disease: epidemiology, clinical manifestations, and diagnosis","author":"Davatchi","year":"2017","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.jaut.2018.09.002_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/art.23450","article-title":"Increased enthesopathy among Beh\u00e7et\u2019s syndrome patients with acne and arthritis: an ultrasonography study","author":"Hatemi","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.09.002_bib8","article-title":"Associations between ankylosing spondylitis, psoriatic arthritis, reiter's disease, the intestinal arthropathies, and behcet's syndrome","author":"Moll","year":"1974","journal-title":"Med. (United States)"},{"key":"10.1016\/j.jaut.2018.09.002_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2018.09.002_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of Interleukin-17A in patients with psoriatic arthritis","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2018.09.002_bib11","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A inhibitor, in ankylosing spondylitis","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2018.09.002_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/nrrheum.2015.147","article-title":"\u2018MHC-I-opathy\u2019-unified concept for spondyloarthritis and Beh\u00e7et disease","author":"McGonagle","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2018.09.002_bib13","article-title":"Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-\u03b1 in early phases of the disease","volume":"95","author":"Emmi","year":"2016","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.jaut.2018.09.002_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-015-2966-2","article-title":"Possible association of proinflammatory cytokines including IL1\u03b2 and TNF\u03b1 with enhanced Th17 cell differentiation in patients with Behcet's disease","author":"Shimizu","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2018.09.002_bib15","article-title":"Up-regulation of th17 and related cytokines in beh\u00e7et\u2019s disease corresponding to disease activity","volume":"31","author":"Na","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.jaut.2018.09.002_bib16","first-page":"130","article-title":"Ustekinumab efficacy and safety in mucocutaneous multi-refractory Beh\u00e7et\u2019s disease","volume":"35","author":"Lopalco","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2018.09.002_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2017.05.002","article-title":"Ustekinumab for Beh\u00e7et\u2019s disease","author":"Mirouse","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2018.09.002_bib18","article-title":"Criteria for diagnosis of beh\u00e7et\u2019s disease. International study group for beh\u00e7et\u2019s disease","author":"International Study Group for Behet\u2019s Disease","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2018.09.002_bib19","article-title":"Management of skin, mucosa and joint involvement of Beh\u00e7et\u2019s syndrome: a systematic review for update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","author":"Leccese","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.09.002_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/jop.12095","article-title":"IL-17C and its receptor IL-17RA\/IL-17RE identify human oral epithelial cell as an inflammatory cell in recurrent aphthous ulcer","volume":"43","author":"Al-Samadi","year":"2014","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.jaut.2018.09.002_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/art.38291","article-title":"The interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond","author":"Smith","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.09.002_bib22","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","author":"Pavelka","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2018.09.002_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/13543784.2016.1181751","article-title":"New therapeutic solutions for Beh\u00e7et\u2019s syndrome","author":"Vitale","year":"2016","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.jaut.2018.09.002_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.13381","article-title":"Beh\u00e7et\u2019s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions","author":"Alpsoy","year":"2016","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jaut.2018.09.002_bib25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/14740338.2017.1338273","article-title":"A safety assessment of biological therapies targeting the IL-23\/IL-17 axis in inflammatory bowel diseases","volume":"16","author":"Verstockt","year":"2017","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.jaut.2018.09.002_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaut.2018.09.002_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","author":"Letko","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaut.2018.09.002_bib28","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","author":"McInnes","year":"2017","journal-title":"Rheumatol. (United Kingdom)"},{"key":"10.1016\/j.jaut.2018.09.002_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/1744666X.2016.1224658","article-title":"Secukinumab for the treatment of psoriatic arthritis","author":"Baronaite Hansen","year":"2016","journal-title":"Expet Rev. Clin. Immunol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841118304347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841118304347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:20:31Z","timestamp":1760257231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841118304347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":29,"alternative-id":["S0896841118304347"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2018.09.002","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of the anti-IL 17 secukinumab in refractory Beh\u00e7et's syndrome: A preliminary study","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2018.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}